Inside anticancer therapy resistance and metastasis. Focus on CD36

Lambrescu, Ioana M.; Gaina, Gisela F.; Ceafalan, Laura C.; Hinescu, Mihail E.

doi:10.7150/jca.90457

International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

open access Global reach, higher impact

Full Text | PDF

J Cancer 2024; 15(6):1675-1686. doi:10.7150/jca.90457 This issue Cite

Review

Inside anticancer therapy resistance and metastasis. Focus on CD36

Ioana M. Lambrescu^1,2, Gisela F. Gaina^1,2, Laura C. Ceafalan^1,2✉, Mihail E. Hinescu^2,3

1. Cell Biology, Neurosciences, and Experimental Myology Laboratory, Victor Babeș Institute of Pathology, 050096 Bucharest, Romania.
2. Department of Cellular and Molecular Biology and Histology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
3. National Institute of Pathology "Victor Babes," 050096 Bucharest, Romania.

Citation:

Lambrescu IM, Gaina GF, Ceafalan LC, Hinescu ME. Inside anticancer therapy resistance and metastasis. Focus on CD36. J Cancer 2024; 15(6):1675-1686. doi:10.7150/jca.90457. https://www.jcancer.org/v15p1675.htm

Other styles

Abstract

Despite recent advances in targeted cancer therapies, drug resistance remains an important setback in tumor control. Understanding the complex mechanisms involved in both innate and acquired drug resistance represents the first step in discovering novel therapeutic agents. Because of its importance in tumorigenesis, progression, and metastasis, lipid metabolism is increasingly garnering attention. CD36 is a membrane receptor at the top of the signaling cascade that transports lipids. Its expression has been repeatedly presented as an unfavorable prognostic factor for various tumor types, raising the question: could CD36 be a critical factor in cancer treatment resistance? In our review, we set out to explore the most prominent studies on the implication of CD36 in resistance to platinum-based drugs and other adjuvant cancer therapies in solid and haematological neoplasia. Moreover, we provide an overview of the latest anti-CD36 cancer therapies, thus opening new perspectives for future personalized medicine.

Keywords: CD36, cancer treatment, drug resistance, chemotherapy, lipid metabolism

Citation styles

APA

Lambrescu, I.M., Gaina, G.F., Ceafalan, L.C., Hinescu, M.E. (2024). Inside anticancer therapy resistance and metastasis. Focus on CD36. Journal of Cancer, 15(6), 1675-1686. https://doi.org/10.7150/jca.90457.

ACS

Lambrescu, I.M.; Gaina, G.F.; Ceafalan, L.C.; Hinescu, M.E. Inside anticancer therapy resistance and metastasis. Focus on CD36. J. Cancer 2024, 15 (6), 1675-1686. DOI: 10.7150/jca.90457.

NLM

CSE

Lambrescu IM, Gaina GF, Ceafalan LC, Hinescu ME. 2024. Inside anticancer therapy resistance and metastasis. Focus on CD36. J Cancer. 15(6):1675-1686.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.